Bispecific Antibodies for PD-1 and VEGF: Impact and Market Dynamics for IO Landscape

Summary:
This podcast, recorded at the 2025 Immuno-Oncology 360º (IO360º) Summit, explores the clinical and market implications of emerging data on bispecific antibodies targeting PD-1 and VEGF and their potential to disrupt existing immunotherapy paradigms.

More specifically: 

• Assessing the potential of this therapeutic approach to challenge established treatments like pembrolizumab by targeting both PD-1 and VEGF
• Insights into how these developments could influence industry trends and investor sentiment
• Forward-looking forecasts on market share and commercial positioning for PD-1/PD-L1 and VEGF-targeting therapies

In this podcast:

• Roy Baynes, MD, PhD, EVP & CMO at Eikon Therapeutics

• Asthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst at Truist Securities

For more information, go to IO360summit.com